Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?

An immediate attention needs to be drawn towards the drawbacks of limited pharmacological options for SCD. Article calls out to conduct more extensive trials in this advanced era of medicine where ambiguity regarding the use of SCD drugs still prevails.